Treatment of Chronic Tinnitus by Xenon Phototherapy on the Stellate Ganglion

Shimizu M*, Matsumi F, Suzuki D and Matsuzuka T

Abstract

Objectives/Hypothesis: To reveal the treatment utility of xenon phototherapy around the stellate ganglion for chronic tinnitus unresponsive to oral medications.

Study design: Outcome research.

Methods: Subjects were 24 patients (13 men, 11 women, mean age: 66 years) with chronic tinnitus unresponsive to oral medications and 8 patients (5 men, 3 women; mean age: 66 years) in the control group. Xenon phototherapy around the stellate ganglion (XPSG) was performed bilaterally for 10 minutes once monthly up to once weekly. At 3 months after the start of xenon phototherapy, treatment outcome was evaluated using the Tinnitus Handicap Inventory (THI) and a Numerical Rating Scale (NRS).

Results: No adverse effects of xenon phototherapy were observed. THI and NRS score were correlative. Wilcoxon’s signed rank test revealed a significant improvement in THI (p<0.05) and NRS score (p=0.01) at 3 months. Patients in NRS scores classified as ‘no handicap’, ‘mild’ and ‘severe’ groups showed improvement (p<0.05) at 3 months. THI scores improved in the severe group (p<0.05). THI and NRS score did not statistically significantly differences in the control group.

Conclusion: Although this study was preliminarily, XPSG improved patient’s symptom of tinnitus measured by THI and NRS scores. XPSG was noninvasive and smart alternative therapy to SGB and promising treatment for chronic tinnitus unresponsive to oral medications.

Keywords
Tinnitus; Xenon phototherapy; Stellate ganglion block

Introduction

Tinnitus is defined as perceived sound originating in the head [1], and is a common complaint in clinical practice. The pathological physiology of tinnitus is largely unclear and there is no definitive treatment strategy as yet. In inner ear (cochlea) type, when inner hair cells have impaired blood flow, an auditory nerve becomes sensitive and is known to cause tinnitus. Stellate ganglion block (SGB) is widely used to alleviate pain and improve blood flow and is one of option for treatment strategy as yet. In inner ear (cochlea) type, when inner hair cells have impaired blood flow, an auditory nerve becomes sensitive and is known to cause tinnitus. Stellate ganglion block (SGB) is widely used to alleviate pain and improve blood flow and is one of option for treatment strategy as yet.

Xenon phototherapy around the stellate ganglion (XPSG) was reported as a safe and simple procedure, and has been performed to treat various clinical cases of pain in head and neck regions and orthopedic Clinics. In this study, XPSG was evaluated for the treatment of chronic tinnitus.

Materials and Methods

Subjects

The study was approved by the Institutional Review Board and Ethics Committee of the Fukushima Medical University. From April to October 2014, there were 30 patients with chronic tinnitus who had been treated at the otolaryngology outpatient clinic at the Fukushima Medical University Hospital and the Hoshi General Hospital. Magnetic resonance angiography was performed to exclude patients with organic lesions such as acoustic neuroma and inner ear malformation. In total, 24 eligible patients (13 men, 11 women; 66 ± 9.3 years old (mean ± SD), range 45-82 years) who were unresponsive to oral medications more than one month were identified; ineffective medication included, vitaminB12, Kampo (Chinese/Japanese traditional herbal medicines), drugs for improving blood circulation, such as nicotinamide, papaverine hydrochloride and adenosine triphosphate disodium hydrate (ATP) has the function to increase blood flow of the inner ear, and vitamin B12 has the effect of improve an obstacle sensory function. Disease duration ranged 6-156 months; 45 ± 9.1 months (mean ± SD). All patients consented to xenon phototherapy in this study. While the patients were receiving XPSG, drugs against tinnitus were discontinued, and anti-anxiety agents or sleep aids were gradually tapered with consultation. In addition, 8 patients (5 men, 3 women; mean ± SD 66 ± 12 years old, range 37-78 years, 20 ± 7.0 months mean ± SD, disease duration ranged 7-84 months) was performed as control group not to receive Xenon light irradiation (Table 1).

Methods of XPSG

The xenon phototherapy device Phos-01 (Nihon Iko Co., Tokyo, Japan) was used to illuminate the skin region above the stellate ganglion bilaterally with pulses duration once every 4 s in a 10-min session for XPSG (Figure 1a,b). The xenon light arrives at from the skin bottom approximately 7 cm, and the spectral range of xenon light has been 260–1100 nm and 18J once every emission, it has excellent water and blood permeability and penetrates not only the surface layer, but also deep layers of biological tissues because of the wavelengths with different tissue penetration properties [2] (Figure 1c). During the 3-month study period, phototherapy sessions were performed once monthly up to once weekly depending on the frequency of each patient’s hospital visits.

The Tinnitus Handicap Inventory (THI) and a Numerical Rating Scale (NRS) were completed by patients to evaluate subjective tinnitus before and 3 months after the start of xenon phototherapy. THI is the questionnaire method consisting of 25 questions for assessment of subjective symptoms of tinnitus. The score reflects subjective pain caused by tinnitus in points up to 100 [3]. It is classified into four categories based on the total score: 0-16 as ‘no handicap’, 18–36 as ‘mild’, 38–56 as ‘moderate’, and 58–100 as ‘severe’. NRS is the scale grading pain caused by tinnitus into levels from ‘0’ to ‘10’. It is used for...
and 3 month after the start of XPSG, THI score overall statistically significantly improved (p<0.05, Figure 3a,3b). THI and NRS scores (mean ± SEM) before and 3 months after XPSG are shown according to severity of tinnitus in Table 1. Among the different severity classes, there was highly significant improvement in the ‘severe’ group (p<0.05, Table 2). More than 20 points of THI reduction was observed in 5 patients (20.8%). THI scores did not statistically significantly differences in the control group (Figure 3c).

Comparison of NRS score

NRS score before the start of XPSG ranged from 2 to 10, mean and median score were 5.9 and 6, respectively (Figure 2b). NRS score 3 month after the start of XPSG ranged from 0 to 8, mean and median score were 4.1 and 4, respectively. Comparing before and 3 month after the start of XPSG, NRS score statistically significantly improved (p<0.01, Figure 4a,4b). NRS scores statistically significantly improved 3 months after therapy for ‘no handicap’, ‘mild’ and ‘severe’ groups of patients (Table 2). NRS scores did not statistically significantly differences in the control group (Figure 4c).

Discussion

Tinnitus is perception of unpleasant sound with no corresponding external sound sources [1] and is a common complaint in clinical practice. The prevalence of tinnitus is reported to be around 15% of general population [6] and that of severe tinnitus affecting everyday life is to be around 1-8%. However, the pathophysiology of tinnitus has not been clear and there is no definitive treatment strategy as yet. Although multidisciplinary approaches involving psychotherapy,
drug and acoustic therapy have conventionally been recommended for chronic tinnitus, they are yet to be fully established and the treatment remains a challenge.

The mechanism of tinnitus is broadly classified as peripheral type when the responsive anatomical site is the inner ear (cochlea) or auditory nerve, or as central type when the responsive anatomical site is in the central nervous system. Peripheral tinnitus is often associated with inner ear hearing loss mostly due to abnormal discharge of the cochlear nerve fibers due to blood flow disturbances in the cochlea [6]. In inner ear (cochlea) type, when inner hair cells have impaired blood flow, an auditory nerve becomes sensitive and is known to cause tinnitus [7]. According to Moller et al. [8] tinnitus subsides or resolves in approximately 40% of the patients treated with decompression of the cochlear nerve and blood vessels [8]. In addition to oral medications such as steroids, ones for improving blood circulation, and Kampo that are commonly prescribed for tinnitus, and also stellate ganglion block (SGB) is performed in pain clinics [9,10]. SGB is widely used to alleviate pain and improve blood flow in patients with facial pain, shingles, facial nerve paralysis, sudden hearing loss, and many other pathological conditions. However, because the needle puncture site in the procedure is close to the vertebral artery and recurrent laryngeal nerve, SGB carries a high risk of serious complications including recurrent laryngeal nerve paralysis, subdural and subarachnoidal block, pyogenic spondylitis, and retropharyngeal or cervicomediastinal or mediastina hematoma [11,12].

In addition, relatively few physicians in otolaryngology practice are highly experienced in SGB. In many patients, inner ear hearing loss is accompanied by tinnitus due to primarily impaired blood flow in the cochlea. SGB has been used widely in clinical settings to improve impaired blood flow in the head and neck associated with various diseases.

The xenon phototherapy has been used for vasodilatation and wound healing [13]. The popularity of XPSG has been growing in recent years due to its safety, simplicity, and comparable efficacy with SGB. However, no definitive treatment for tinnitus has been established thus far.

In this study, we selected non-invasive and bio-permeable xenon light with steady and optimal light energy to irradiate the stellate ganglion located deep inside the neck region, anterior to the transverse process of the 7th cervical vertebra and posterior to the vertebral artery. The xenon gas is used in xenon phototherapy as a medium to generate so-called xenon light, a multi-wavelength white
light with a broad wavelength ranging from the ultraviolet to infrared light, which illuminates light including wide wavelength distribution [14]. Although the spectral range of the light is 160–1100 nm, with a broad peak at around 700–900 nm, it has excellent water and blood permeability and penetrates the surface layer as well as deep layers of biological tissues [14]. Depth of the stellate ganglion is reported to be about 24 mm [15], and the xenon light reaches about 7 cm depth in the connective tissue. Therefore, XPSG can easily affect the stellate ganglion. Due to pulsed illumination and the special wide probe, the xenon phototherapy device was designed safely and simply to irradiate a wide area with high energy. In this study, there were no adverse events, such as Horner sign, burn, and hematoma. One patient had light dizziness only the first time. The change of the blood circulation may have been the cause. XPSG is safe considering high risks associated with needle puncture in SGB. According to the manufacturer’s specifications, xenon phototherapy is contraindicated for safety reasons in patients with a pacemaker because of the proximity between the treatment probe and the pacemaker.

The mechanism of action and clinical efficacy of xenon phototherapy include vasodilation, promotion of tissue repair, and anti-inflammation. The therapy is performed to facilitate blood flow [15], pain relief [16,17], and wound repair [13,18]. For tinnitus, the mechanism through which xenon phototherapy improves blood flow disturbances in the inner ear appears to be as follows: XPSG interrupts nerve conduction within the ganglion and thus suppresses the activity of the sympathetic nerves by alleviating tension and dilating peripheral blood vessels, thereby improving blood flow in the head and neck region [19].

After XPSG, THI and NRS score overall statistically significantly improved in the present study. More than 20 points of THI reduction, that was considered to be clinically significant by Newman et al. [20], was observed in 5 patients (20.8%). patients in the ‘severe’ tinnitus group improved significantly in outcome with XPSG. Based on these clear improvements in THI and NRS scores, XPSG can be considered as a noninvasive and smart alternative therapy to SGB and promising treatment for chronic tinnitus unresponsive to oral medications. In this study, THI and NRS scores have not been statistically significant differences in the control group. As this study is a preliminary, further large scale studies to validate our results are warranted.

**Conclusion**

- XPSG was performed to investigate its efficacy in the current preliminary study in 24 patients with chronic tinnitus unresponsive to oral medications, 8 patients in the control group.
- Statistically significant differences were observed in overall tinnitus THI and NRS scores by XPSG before and 3 months after treatment. Statistically significant differences were not observed THI and NRS scores in the control group.
- XPSG was noninvasive and smart alternative therapy to SGB and promising treatment for chronic tinnitus. However, any adverse reactions should be closely monitored.

**References**


**Table 2:** Changes in tinnitus handicap inventory (THI) and Numerical Rating Scale (NRS) before and 3 months after xenon phototherapy.

<table>
<thead>
<tr>
<th>Severity of tinnitus (THI before treatment)</th>
<th>Number of Patients</th>
<th>THI score Before</th>
<th>NRS score Before</th>
<th>3 months</th>
<th>3 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>'No handicap'</td>
<td>7</td>
<td>10 ± 2.0</td>
<td>9.1 ± 2.5</td>
<td>4.3 ± 0.8</td>
<td>4.2 ± 0.8</td>
</tr>
<tr>
<td>'Mild'</td>
<td>7</td>
<td>30 ± 1.4</td>
<td>30 ± 5.6</td>
<td>5.4 ± 0.6</td>
<td>5.4 ± 0.6</td>
</tr>
<tr>
<td>'Moderate'</td>
<td>3</td>
<td>45 ± 5.5</td>
<td>37 ± 9.3</td>
<td>6.0 ± 1.2</td>
<td>6.0 ± 1.2</td>
</tr>
<tr>
<td>'Severe'</td>
<td>7</td>
<td>74 ± 3.4</td>
<td>49 ± 5.8</td>
<td>8.0 ± 0.4</td>
<td>8.0 ± 0.4</td>
</tr>
<tr>
<td>Total</td>
<td>24</td>
<td>39 ± 5.4</td>
<td>30 ± 4.1</td>
<td>5.9 ± 0.4</td>
<td>5.9 ± 0.4</td>
</tr>
</tbody>
</table>

*Statistically significant differences were observed in overall tinnitus THI and NRS scores by XPSG before and 3 months after treatment. Statistically significant differences were not observed THI and NRS scores in the control group.

*XPFG was noninvasive and smart alternative therapy to SGB and promising treatment for chronic tinnitus. However, any adverse reactions should be closely monitored.*